Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade

Experimental and Molecular Medicine

Volumn 45, Issue 11, 2013, Pages

  Singh, Rohit ^a   Kim, Woo Jin ^a   Kim, Pyeung Hyeun ^a   Hong, Hyo Jeong ^a  

^a Kangwon National University   (South Korea)

Author keywords

Combination treatment; Gastric cancer; HER2; Trastuzumab; VEGF Trap

Indexed keywords

AFLIBERCEPT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLACENTAL GROWTH FACTOR; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG SCREENING; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE; ANTAGONISTS AND INHIBITORS; NEOVASCULARIZATION, PATHOLOGIC; STOMACH NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892167721     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.111     Document Type: Article

References (54)

1. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
3. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-
4. alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
5. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-Targeted antibody therapy. Oncogene 2006; 25: 6986-6996.
6. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-1654.
7. Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
9. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. Multinational study of the efficacy and safety of humanized anti- HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2639.
10. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
11. Nahta R, Esteva FJ. Herceptin: Mechanisms of action and resistance. Cancer Lett 2006; 232: 123-138.
12. Fukumura D, Xavier R, Sugiura T, Chen Y, Park E, Lu N et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-725.
13. Harmey J, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 1998; 5: 271-278.
14. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an anti-Angiogenic cocktail. Nature 2002; 416: 279-280.
15. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693.
16. Figg WD, Folkman J. Angiogenesis: An Integrative Approach from Science to Medicine. Springer: New York, NY, USA, 2008.
17. Le X, Mao W, Lu C, Thornton A, Heymach JV, Sood AK et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008; 7: 3747-3758.
18. Alami N, Sun Y, De P, Benmassaoud AM, Wang Y, Leyland-Jones B. Combination effects of herceptin, pertuzumab and bevacizumab in a HER2-overexpressing breast cancer xenograft model. Cancer Res 2009; 69: 4058 (abstract).
19. Pegram M, Yeon C, Ku N, Gaudreault J, Slamon D. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004; 88: S124-S125 (abstract 3039).
20. Pegram M, Chan D, Dichmann R, Tan-Chiu E, Yeon C, Durna L et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-Amplified breast cancer. Breast Cancer Res Treat 2006; 100: S28-S29 (abstract 301).
21. Pierga J, Petit T, Delozier T, Ferrero J, Campone M, Gligorov J et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): An open-label, single-Arm phase 2 study. Lancet Oncol 2012; 13: 375-384.
22. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380.
23. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
24. Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
25. Ellis LM, Hicklin DJ. VEGF-Targeted therapy: Mechanisms of anti-Tumour activity. Nat Rev Cancer 2008; 8: 579-591.
26. Miao H, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000; 14: 2532-2539.
27. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154-165.
28. Donnini S, Machein MR, Plate KH, Weich HA. Expression and localization of placenta growth factor and P1GF receptors in human meningiomas. J Pathol 1999; 189: 66-71.
29. André T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, Prévot S et al. VEGF, VEGF-B, VEGF-C, and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000; 86: 174-181.
30. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-Angiogenic therapy? Nat Rev Cancer 2008; 8: 942-956.
31. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748.
32. Willett CG, Duda DG, Di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026.
33. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009; 106: 6152-6157.
34. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002; 82: 673-700.
35. Lieu C, Tran H, Jiang Z, Mao M, Overman M, Eng C et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. J Clin Oncol 2011; 29: 3533.
36. Ebos JM, Kerbel RS. Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 210-221.
37. Kumar R, Crouthamel M, Rominger D, Gontarek R, Tummino P, Levin R et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101: 1717-1723.
38. Bergers G, Hanahan D. Modes of resistance to anti-Angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
39. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X et al. AVEREL: A Randomized Phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719-1725.
40. Lin N, Seah D, Gelman R, Desantis S, Mayer E, Isakoff S et al. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013; 139: 403-410.
41. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M et al. VEGFTrap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398.
42. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185.
43. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 2012; 38: 484-493.
44. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer 2010; 46: 1949-1959.
45. Bang Y, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
46. Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S et al. Anti-Tumor and anti-metastatic effects of human-vascular-endothelialgrowth- factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998; 77: 933-936.
47. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. J Clin Oncol 2011; 29: 3968-3976.
48. Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA, Lee D et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32: 89-95.
49. Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70: 2213-2223.
50. Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2- mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003; 98: 1377-1385.
51. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21: 177-184.
52. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006; 12: 904-916.
53. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30: 2119-2127.
54. Van Cutsem E, Jayson G, Dive C, Dilba P, de Haas S, Wild N et al. Analysis of blood plasma factors in the AVITA Phase III Randomized Study of bevacizumab (bev) with gemcitabine-erlotinib (ge) in patients (pts) with metastatic pancreatic cancer (mPC). Eur J Cancer 2011; 47: (abstract 803).